טוען...
A Prospective, Phase I/II Study of Everolimus and Temozolomide in Patients with Advanced Pancreatic Neuroendocrine Tumor
BACKGROUND: Both everolimus and temozolomide are associated with single-agent activity in patients with pancreatic neuroendocrine tumor (NET). We performed a phase I/II study to evaluate the safety and efficacy of temozolomide in combination with everolimus in patients with advanced pancreatic NET....
שמור ב:
| הוצא לאור ב: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4308727/ https://ncbi.nlm.nih.gov/pubmed/23733618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28142 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|